EVOLTRA, known generically as clofarabine, is a chemotherapy medication used primarily in the treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric patients who have not responded to or have relapsed after receiving standard therapy. It belongs to a class of drugs known as nucleoside metabolic inhibitors, which work by interfering with the DNA synthesis of cancer cells, thereby inhibiting their growth and proliferation. EVOLTRA is administered intravenously and is noted for its potential to provide a therapeutic option for patients with few other treatment alternatives. However, like many chemotherapy drugs, it can cause a range of side effects, and its use is carefully monitored by healthcare professionals to balance the benefits of treatment against potential risks.